{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:36:27Z","timestamp":1767832587414,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic","award":["VEGA 1\/0112\/17"],"award-info":[{"award-number":["VEGA 1\/0112\/17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40261-017-0559-3","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T11:03:10Z","timestamp":1502190190000},"page":"1047-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-1574","authenticated-orcid":false,"given":"Martin","family":"Wawruch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Zatko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Gejza","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Luha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Wimmerova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Matalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kukumberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Murin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Havelkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,8]]},"reference":[{"key":"559_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000328650","volume":"32","author":"N Venketasubramanian","year":"2011","unstructured":"Venketasubramanian N, R\u00f6ther J, Bhatt DL, et al. Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry. Cerebrovasc Dis. 2011;32:254\u201360.","journal-title":"Cerebrovasc Dis."},{"key":"559_CR2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/01.WNL.0000129482.70315.2F","volume":"62","author":"MD Hill","year":"2004","unstructured":"Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology. 2004;62:2015\u201320.","journal-title":"Neurology."},{"key":"559_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549\u201359.","journal-title":"N Engl J Med."},{"key":"559_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40266-014-0212-2","volume":"31","author":"MK Arnan","year":"2014","unstructured":"Arnan MK, Burke GL, Bushnell C. Secondary prevention of stroke in the elderly: focus on drug therapy. Drugs Aging. 2014;31:721\u201330.","journal-title":"Drugs Aging."},{"key":"559_CR5","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45:2160\u2013236.","journal-title":"Stroke."},{"key":"559_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/sj.jcbfm.9600116","volume":"25","author":"M Endres","year":"2005","unstructured":"Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005;25:1093\u2013110.","journal-title":"J Cereb Blood Flow Metab."},{"key":"559_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40520-015-0435-z","volume":"28","author":"A Giardini","year":"2016","unstructured":"Giardini A, Martin MT, Cahir C, et al. Toward appropriate criteria in medication adherence assessment in older persons: position paper. Aging Clin Exp Res. 2016;28:371\u201381.","journal-title":"Aging Clin Exp Res."},{"key":"559_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00228-007-0340-2","volume":"63","author":"J Hasford","year":"2007","unstructured":"Hasford J, Schr\u00f6der-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:1055\u201361.","journal-title":"Eur J Clin Pharmacol."},{"key":"559_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691\u2013705.","journal-title":"Br J Clin Pharmacol."},{"key":"559_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40261-016-0388-9","volume":"36","author":"A Horn","year":"2016","unstructured":"Horn A, Zeuner H, Wolf H, Schnitker J, W\u00fcstenberg E, GRAZAX LQ-study group. Health-related quality of life during routine treatment with the SQ-standardised grass allergy immunotherapy tablet: a non-interventional observational study. Clin Drug Investig. 2016;36:453\u201362.","journal-title":"Clin Drug Investig."},{"key":"559_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40261-016-0395-x","volume":"36","author":"L Molina","year":"2016","unstructured":"Molina L, Recinos B, Paz B, et al. Factors related to early clinical effects of quetiapine extended-release: a multinational, prospective, observational study. Clin Drug Investig. 2016;36:491\u20137.","journal-title":"Clin Drug Investig."},{"key":"559_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1253\/circj.CJ-15-0753","volume":"80","author":"PS Chen","year":"2016","unstructured":"Chen PS, Cheng CL, Kao Yang YH, Li YH. Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J. 2016;80:731\u20137.","journal-title":"Circ J."},{"key":"559_CR13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1212\/WNL.0b013e31822f0423","volume":"77","author":"CD Bushnell","year":"2011","unstructured":"Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011;77:1182\u201390.","journal-title":"Neurology."},{"key":"559_CR14","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00228-012-1293-7","volume":"68","author":"K \u00d8stergaard","year":"2012","unstructured":"\u00d8stergaard K, Hallas J, Bak S, Christensen RD, Gaist D. Long-term use of antiplatelet drugs by stroke patients: a follow-up study based on prescription register data. Eur J Clin Pharmacol. 2012;68:1631\u20137.","journal-title":"Eur J Clin Pharmacol."},{"key":"559_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40266-016-0365-2","volume":"33","author":"M Wawruch","year":"2016","unstructured":"Wawruch M, Zatko D, Wimmer G Jr, et al. Factors influencing non-persistence with antiplatelet medications in elderly patients after ischaemic stroke. Drugs Aging. 2016;33:365\u201373.","journal-title":"Drugs Aging."},{"key":"559_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/pds.4148","volume":"26","author":"M Wawruch","year":"2017","unstructured":"Wawruch M, Zatko D, Wimmer G Jr, et al. Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke. Pharmacoepidemiol Drug Saf. 2017;26:201\u20137.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"559_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/archneurol.2010.190","volume":"67","author":"CD Bushnell","year":"2010","unstructured":"Bushnell CD, Zimmer LO, Pan W, Adherence Evaluation After Ischemic Stroke-Longitudinal Investigators, et al. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol. 2010;67:1456\u201363.","journal-title":"Arch Neurol."},{"key":"559_CR18","unstructured":"ICD\u201410th International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: WHO; 1992."},{"key":"559_CR19","unstructured":"Guidelines for ATC classification and DDD assignment 2016. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2016."},{"key":"559_CR20","volume-title":"Biostatistical methods in epidemiology","author":"SC Newman","year":"2001","unstructured":"Newman SC. Biostatistical methods in epidemiology. Chichester: Wiley; 2001."},{"key":"559_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/STROKEAHA.109.566950","volume":"41","author":"EL Glader","year":"2010","unstructured":"Glader EL, Sj\u00f6lander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397\u2013401.","journal-title":"Stroke."},{"key":"559_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1742-1241.2011.02706.x","volume":"65","author":"MC Wong","year":"2011","unstructured":"Wong MC, Jiang JY, Griffiths SM. Adherence to lipid-lowering agents among 11,042 patients in clinical practice. Int J Clin Pract. 2011;65:741\u20138.","journal-title":"Int J Clin Pract."},{"key":"559_CR23","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/pds.3526","volume":"22","author":"JR Warren","year":"2013","unstructured":"Warren JR, Falster MO, Fox D, Jorm L. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf. 2013;22:1298\u2013307.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"559_CR24","first-page":"1","volume":"15","author":"S Sehatzadeh","year":"2015","unstructured":"Sehatzadeh S. Is transient ischemic attack a medical emergency? An evidence-based analysis. Ont Health Technol Assess Ser. 2015;15:1\u201345.","journal-title":"Ont Health Technol Assess Ser."},{"key":"559_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11883-016-0619-9","volume":"18","author":"KM Goldstein","year":"2016","unstructured":"Goldstein KM, Zullig LL, Bastian LA, Bosworth HB. Statin adherence: does gender matter? Curr Atheroscler Rep. 2016;18:63.","journal-title":"Curr Atheroscler Rep."},{"key":"559_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/pds.2268","volume":"21","author":"M Sj\u00f6lander","year":"2012","unstructured":"Sj\u00f6lander M, Eriksson M, Glader EL. Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study. Pharmacoepidemiol Drug Saf. 2012;21:911\u20139.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"559_CR27","doi-asserted-by":"publisher","first-page":"i3305","DOI":"10.1136\/bmj.i3305","volume":"353","author":"Y Vinogradova","year":"2016","unstructured":"Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ. 2016;353:i3305.","journal-title":"BMJ."},{"key":"559_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00228-015-1996-7","volume":"72","author":"A Citarella","year":"2016","unstructured":"Citarella A, Linder M, Kieler H, et al. Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. Eur J Clin Pharmacol. 2016;72:349\u201357.","journal-title":"Eur J Clin Pharmacol."},{"key":"559_CR29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/PPA.S87551","volume":"9","author":"E Costa","year":"2015","unstructured":"Costa E, Giardini A, Savin M, et al. Interventional tools to improve medication adherence: review of literature. Patient Preference Adherence. 2015;9:1303\u201314.","journal-title":"Patient Preference Adherence."},{"key":"559_CR30","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1001\/archinte.164.21.2343","volume":"164","author":"RW Grant","year":"2004","unstructured":"Grant RW, O\u2019Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164:2343\u20138.","journal-title":"Arch Intern Med."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0559-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T15:15:32Z","timestamp":1581952532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0559-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,8]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0559-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,8]]},"assertion":[{"value":"8 August 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by a Grant from the Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA 1\/0112\/17. The providers of this Grant played no role in the design, methods, data collection, analysis or interpretation of the data, preparation of the paper or in the decision to submit the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors of this article declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Under the applicable legal requirements of our country, the study did not require the approval of an Ethics Committee. The rules of personal data confidentiality were fully respected.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}